Rituximab-Based Regimen As First-Line Treatment in Chinese Patients with Follicular Lymphoma: Three-Year Safety Data from a Prospective, Observational Study

被引：0
|
作者：
Wu, Jianqiu
Song, Yongping
Su, Liping
Zhang, Mingzhi
Li, Wei
Hu, Yu
Zhang, Xiaohong
Gao, Yuhuan
Niu, Zuoxing
Feng, Ru
Wang, Wei
Peng, Jiewen
Li, Xiaolin
Ouyang, Xuenong
Wu, Changping
Zhang, Weijing
Zeng, Yun
Xiao, Zhen
Liang, Yingmin
Zhuang, Yongzhi
Wang, Jishi
Sun, Zimin
Bai, Hai
Cui, Tongjian
Feng, Jifeng
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5167
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database
    Janikova, Andrea
    Bortlicek, Zbynek
    Campr, Vit
    Kopalova, Natasa
    Benesova, Katerina
    Hamouzova, Jitka
    Belada, David
    Prochazka, Vit
    Pytlik, Robert
    Vokurka, Samuel
    Pirnos, Jan
    Duras, Juraj
    Mocikova, Heidi
    Mayer, Jiri
    Trneny, Marek
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1094 - 1103
  • [42] RITUXIMAB, MITOXANTRONE, ETOPOSIDE AND CYCLOPHOSPHAMIDE REGIMEN AS FIRST-LINE TREATMENT IN ELDERLY FRAIL PATIENTS WITH AGGRESSIVE NON-HODGKIN'S LYMPHOMA
    Kovalchuk, S.
    Rigacci, L.
    Puccini, B.
    Lancia, F.
    Mannelli, L.
    Benelli, G.
    Bosi, A.
    HAEMATOLOGICA, 2015, 100 : 149 - 149
  • [43] Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study
    Jianqiu Wu
    Yongping Song
    Liping Su
    Li Xu
    Tingchao Chen
    Zhiyun Zhao
    Mingzhi Zhang
    Wei Li
    Yu Hu
    Xiaohong Zhang
    Yuhuan Gao
    Zuoxing Niu
    Ru Feng
    Wei Wang
    Jiewen Peng
    Xiaolin Li
    Xuenong Ouyang
    Changping Wu
    Weijing Zhang
    Yun Zeng
    Zhen Xiao
    Yingmin Liang
    Yongzhi Zhuang
    Jishi Wang
    Zimin Sun
    Hai Bai
    Tongjian Cui
    Jifeng Feng
    BMC Cancer, 16
  • [44] Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study
    Wu, Jianqiu
    Song, Yongping
    Su, Liping
    Xu, Li
    Chen, Tingchao
    Zhao, Zhiyun
    Zhang, Mingzhi
    Li, Wei
    Hu, Yu
    Zhang, Xiaohong
    Gao, Yuhuan
    Niu, Zuoxing
    Feng, Ru
    Wang, Wei
    Peng, Jiewen
    Li, Xiaolin
    Ouyang, Xuenong
    Wu, Changping
    Zhang, Weijing
    Zeng, Yun
    Xiao, Zhen
    Liang, Yingmin
    Zhuang, Yongzhi
    Wang, Jishi
    Sun, Zimin
    Bai, Hai
    Cui, Tongjian
    Feng, Jifeng
    BMC CANCER, 2016, 16
  • [45] Efficacy and safety of rituximab biosimilars or reference product as first-line treatment in patients with low-tumour-burden follicular lymphoma: A systematic review and meta-analysis
    Yang, Liu
    Zheng, Zhiwei
    Li, Na
    Zheng, Bin
    Liu, Maobai
    Cai, Hongfu
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (12) : 1923 - 1931
  • [46] The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study
    Galimberti, Sara
    Ciabatti, Elena
    Ercolano, Giacomo
    Grassi, Susanna
    Guerrini, Francesca
    Cecconi, Nadia
    Rousseau, Martina
    Cervetti, Guilia
    Mazziotta, Francesco
    Iovino, Lorenzo
    Falzetti, Franca
    Falcinelli, Flavio
    Bosi, Alberto
    Rigacci, Luigi
    Kovalchuk, Sofia
    Vallisa, Daniele
    Macchia, Lucia
    Ciancia, Eugenio
    Petrini, Mario
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [47] Subcutaneous Rituximab and Chemotherapy Achieves Similar Overall Response Rates to Intravenous Rituximab in First-Line Follicular Lymphoma: Efficacy and Safety Results of the Phase III SABRINA Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 6 - 7
  • [48] SUBCUTANEOUS RITUXIMAB AND CHEMOTHERAPY ACHIEVES SIMILAR OVERALL RESPONSE RATES TO INTRAVENOUS RITUXIMAB IN FIRST-LINE FOLLICULAR LYMPHOMA: EFFICACY AND SAFETY RESULTS OF THE PHASE III SABRINA STUDY
    Davies, A.
    Merli, F.
    Mihaljevic, B.
    Mercadal, S.
    Solal-Celigny, P.
    Boehnke, A.
    Berge, C.
    Cambon, N.
    Macgregor, L.
    Brewster, M.
    Barrett, M.
    MacDonald, D.
    HAEMATOLOGICA, 2014, 99 : 225 - 225
  • [49] Impact onMedical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare
    Griffiths, Robert I.
    Gleeson, Michelle L.
    Mikhael, Joseph
    Danese, Mark D.
    JOURNAL OF CANCER EPIDEMIOLOGY, 2012, 2012
  • [50] Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study
    Tamar Berger
    Tzippy Shochat
    Shlomzion Aumann
    Boaz Nachmias
    Neta Goldschmidt
    Nurit Horesh
    Reut Harel
    Ariel Aviv
    Ella Shmerts
    Uri Abadi
    Shai Shimony
    Pia Raanani
    Anat Gafter‑Gvili
    Ronit Gurion
    Annals of Hematology, 2023, 102 : 2127 - 2136
12345